Cigna Approves Coverage for AI Cardiovascular Imaging Tech, Expanding Access to 61 Million Americans
ByAinvest
Tuesday, Sep 30, 2025 10:45 am ET1min read
CI--
Joining UnitedHealthcare and EviCore, Cigna's coverage decision recognizes the clinical and economic value of Artificial Intelligence Enabled CT Based Quantitative Coronary Tomography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) technology. This advanced imaging technology enhances diagnostic accuracy and supports clinicians in making more informed care decisions [1].
With more than 16 million covered lives, Cigna's move aims to improve patient outcomes and reduce long-term healthcare costs. The technology's upcoming CPT I code, set to go into effect in January 2026, further solidifies its integration into the healthcare system [1].
The rapid adoption of AI-QCT reflects mounting clinical evidence that the technology enhances diagnostic accuracy and reduces healthcare expenditures. This is particularly significant given that cardiovascular disease remains the leading cause of death in the United States [1].
Cigna's focus on integrating innovative technologies is expected to enhance customer loyalty and promote sustainable growth. The company's decision underscores its commitment to improving patient care and reducing healthcare costs through the adoption of cutting-edge technologies [1].
Cigna has approved coverage for Cleerly's AI-powered cardiovascular imaging technology, joining UnitedHealthcare and EviCore. This move expands coverage to over 61 million Americans, marking a milestone in industry adoption. Cigna's focus on integrating innovative technologies aims to improve patient outcomes and reduce long-term healthcare costs. This approach is expected to enhance customer loyalty and promote sustainable growth.
In a significant development for healthcare technology, Cigna has approved coverage for Cleerly's AI-powered cardiovascular imaging technology. This decision, effective October 1, 2025, marks a milestone in industry adoption, expanding access to over 61 million Americans [1].Joining UnitedHealthcare and EviCore, Cigna's coverage decision recognizes the clinical and economic value of Artificial Intelligence Enabled CT Based Quantitative Coronary Tomography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) technology. This advanced imaging technology enhances diagnostic accuracy and supports clinicians in making more informed care decisions [1].
With more than 16 million covered lives, Cigna's move aims to improve patient outcomes and reduce long-term healthcare costs. The technology's upcoming CPT I code, set to go into effect in January 2026, further solidifies its integration into the healthcare system [1].
The rapid adoption of AI-QCT reflects mounting clinical evidence that the technology enhances diagnostic accuracy and reduces healthcare expenditures. This is particularly significant given that cardiovascular disease remains the leading cause of death in the United States [1].
Cigna's focus on integrating innovative technologies is expected to enhance customer loyalty and promote sustainable growth. The company's decision underscores its commitment to improving patient care and reducing healthcare costs through the adoption of cutting-edge technologies [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet